MX2019007584A - Combinaciones de compuesto de fgf21/agonista de glp-1r con una proporcion de actividades optimizada. - Google Patents

Combinaciones de compuesto de fgf21/agonista de glp-1r con una proporcion de actividades optimizada.

Info

Publication number
MX2019007584A
MX2019007584A MX2019007584A MX2019007584A MX2019007584A MX 2019007584 A MX2019007584 A MX 2019007584A MX 2019007584 A MX2019007584 A MX 2019007584A MX 2019007584 A MX2019007584 A MX 2019007584A MX 2019007584 A MX2019007584 A MX 2019007584A
Authority
MX
Mexico
Prior art keywords
glp
activity ratio
agonist
fgf21
fgf21 compound
Prior art date
Application number
MX2019007584A
Other languages
English (en)
Inventor
Langer Thomas
Evers Andreas
Boscheinen Oliver
Sommerfeld Mark
Göbel Britta
Rudolph Christine
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2019007584A publication Critical patent/MX2019007584A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a combinaciones, composiciones farmacéuticas y moléculas de fusión que comprenden un compuesto de FGF21 (factor de crecimiento de fibroblastos 21) y un agonista de GLP-1R (receptor de péptido similar a glucagón 1) con una proporción de actividades optimizada de agonista de GLP-1R/ compuesto de FGF21. Además se refiere a su uso como medicamentos, en particular para el tratamiento de la obesidad, sobrepeso, síndrome metabólico, diabetes mellitus, retinopatía diabética, hiperglucemia, dislipidemia, esteatohepatitis no alcohólica (EHNA) y/o ateroesclerosis.
MX2019007584A 2016-12-22 2017-12-22 Combinaciones de compuesto de fgf21/agonista de glp-1r con una proporcion de actividades optimizada. MX2019007584A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16306776 2016-12-22
PCT/EP2017/084310 WO2018115401A1 (en) 2016-12-22 2017-12-22 Fgf21 compound / glp-1r agonist combinations with optimized activity ratio

Publications (1)

Publication Number Publication Date
MX2019007584A true MX2019007584A (es) 2019-09-04

Family

ID=57755136

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007584A MX2019007584A (es) 2016-12-22 2017-12-22 Combinaciones de compuesto de fgf21/agonista de glp-1r con una proporcion de actividades optimizada.

Country Status (11)

Country Link
US (3) US10583174B2 (es)
EP (1) EP3558341A1 (es)
JP (2) JP7309606B2 (es)
KR (1) KR102657457B1 (es)
CN (1) CN110087671A (es)
AU (1) AU2017382038A1 (es)
BR (1) BR112019012693A2 (es)
CA (1) CA3047862A1 (es)
MX (1) MX2019007584A (es)
RU (1) RU2019122785A (es)
WO (1) WO2018115401A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018001511A (es) 2015-08-04 2018-08-01 Univ Duke Polimeros furtivos desordenados de forma intrinseca codificados geneticamente para suministro y metodos para usar los mismos.
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
US11467156B2 (en) 2016-06-01 2022-10-11 Duke University Nonfouling biosensors
EP3558341A1 (en) * 2016-12-22 2019-10-30 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
CN107056925B (zh) * 2017-04-28 2022-01-14 中国科学院合肥物质科学研究院 人fgf21突变体、其制备方法及用途
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
US11680083B2 (en) 2017-06-30 2023-06-20 Duke University Order and disorder as a design principle for stimuli-responsive biopolymer networks
JP2021528422A (ja) * 2018-06-21 2021-10-21 サノフイＳａｎｏｆｉ 最適化された活性比を有するｆｇｆ２１化合物／ｇｌｐ−１ｒアゴニストの組合せ
WO2020028806A1 (en) 2018-08-02 2020-02-06 Duke University Dual agonist fusion proteins
WO2020208205A1 (en) * 2019-04-10 2020-10-15 Genfit Combination therapy comprising compounds of formula (i) and glp-1 receptor agonists
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
CN112279920B (zh) * 2019-07-25 2024-01-16 安源医药科技（上海）有限公司 FGF21 Fc融合蛋白、GLP-1 Fc融合蛋白及它们的组合治疗剂和用途
CN111423506B (zh) * 2019-11-08 2023-06-27 成都奥达生物科技有限公司 一种glp-1化合物
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
US11981718B2 (en) * 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
JP2023540662A (ja) * 2020-07-02 2023-09-26 サノフイ 低減された活性を有するｇｌｐ－１ｒアゴニストペプチド
US20220010021A1 (en) 2020-07-02 2022-01-13 Sanofi FGFR1/KLB Targeting Agonistic Antigen-Binding Proteins and Conjugates Thereof with GLP-1R Agonistic Peptides
EP4175660A1 (en) * 2020-07-02 2023-05-10 Sanofi Glp-1r agonist / fgf21 fusion proteins
CN114685643A (zh) * 2020-12-29 2022-07-01 苏州康宁杰瑞生物科技有限公司 一种人glp-1多肽变体及其应用
EP4360642A1 (en) * 2021-06-25 2024-05-01 Gan & Lee Pharmaceuticals Co., Ltd. Pharmaceutical composition of pcsk9 inhibitor and glp-1 receptor agonist
CN116162146B (zh) * 2021-11-24 2023-10-24 成都奥达生物科技有限公司 一种gip-glp-1双激动剂化合物
CN115850503B (zh) * 2022-07-15 2023-09-08 赣江中药创新中心 一种双靶点融合蛋白及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE347901T1 (de) * 1999-01-14 2007-01-15 Amylin Pharmaceuticals Inc Exendine zur glucagon suppression
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
ES2227115T5 (es) * 2000-01-10 2014-10-30 Amylin Pharmaceuticals, Inc. Utilización de exendinas y sus agonistas para el tratamiento de la hipertrigliceridemia
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
WO2010042747A2 (en) 2008-10-10 2010-04-15 Amgen Inc. Fgf21 mutants and uses thereof
JO3469B1 (ar) 2009-05-05 2020-07-05 Amgen Inc طافرات fgf21 واستخداماتها
MX2011011815A (es) 2009-05-05 2012-01-27 Amgen Inc Mutantes fgf21 y usos de los mismos.
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
EP2460527A1 (en) * 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
US20130090285A1 (en) * 2011-06-27 2013-04-11 Phasebio Pharmaceuticals, Inc. Methods of treatment with glp-1 receptor agonists
TW201315742A (zh) * 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
UY34346A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de fusión para tratar trastornos metabólicos
CA2871656A1 (en) 2012-06-11 2013-12-19 Eli Lilly And Company Fibroblast growth factor 21 variants
SG11201500682WA (en) * 2012-09-07 2015-02-27 Sanofi Sa Fusion proteins for treating a metabolic syndrome
TW201731867A (zh) 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
EP3558341A1 (en) * 2016-12-22 2019-10-30 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
JP2023540662A (ja) * 2020-07-02 2023-09-26 サノフイ 低減された活性を有するｇｌｐ－１ｒアゴニストペプチド
EP4175660A1 (en) * 2020-07-02 2023-05-10 Sanofi Glp-1r agonist / fgf21 fusion proteins

Also Published As

Publication number Publication date
US20180236037A1 (en) 2018-08-23
AU2017382038A1 (en) 2019-08-08
US20200261542A1 (en) 2020-08-20
BR112019012693A2 (pt) 2019-11-19
RU2019122785A (ru) 2021-01-22
RU2019122785A3 (es) 2021-04-15
EP3558341A1 (en) 2019-10-30
US20220401523A1 (en) 2022-12-22
KR20190099468A (ko) 2019-08-27
US10583174B2 (en) 2020-03-10
JP7309606B2 (ja) 2023-07-18
KR102657457B1 (ko) 2024-04-12
CA3047862A1 (en) 2018-06-28
WO2018115401A1 (en) 2018-06-28
CN110087671A (zh) 2019-08-02
JP2023071932A (ja) 2023-05-23
JP2020504611A (ja) 2020-02-13

Similar Documents

Publication Publication Date Title
MX2019007584A (es) Combinaciones de compuesto de fgf21/agonista de glp-1r con una proporcion de actividades optimizada.
PH12015500194A1 (en) Fusion proteins for treating a metabolic syndrome
MX2018005387A (es) Variantes de fgf21.
BR112012017949A2 (pt) composição farmacêutica para o tratamento de uma síndrome metabólica
TN2017000148A1 (en) Co-agonists of the glucagon and glp-1 receptors
WO2017009236A3 (en) New exendin-4 derivatives as selective peptidic dual glp-1 / glucagon receptor agonists
MX2016013244A (es) Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon.
CU20130073A7 (es) Péptidos derivados del factor de crecimiento de fibroblastos 21 ( fgf21) útiles como reguladores metabólicos
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
PH12015500688A1 (en) Exendin-4 derivatives as dual glp1/glucagon agonists
MX2016013248A (es) Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4.
MX362190B (es) Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon.
PH12016502391A1 (en) Composition for treating diabetes, comprising long-acting insulin analogue conjugate and long-acting insulinotropic peptide conjugate
MX2014015257A (es) Proteinas del factor 21 de crecimiento de fibroblasto.
BRPI0924307B8 (pt) análogos de oxintomodulina
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
WO2010054326A3 (en) C-terminal fragments of glucagon-like peptide-1 (glp-1)
MX2020008387A (es) Usos terapeuticos de agonistas glp1r.
MX2017004614A (es) Preparacion compuesta, que contiene derivado novedoso de acido 3-(4-(benciloxi)fenil)hex-4-inoico y otro ingrediente activo, para prevenir o tratar enfermedades metabolicas.
MX366685B (es) Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos.
CR20220279A (es) Análogos de incretina y sus usos
IN2012DN00977A (es)